Presentation is loading. Please wait.

Presentation is loading. Please wait.

Lucy Wales, FRCS, MD, Martin Gosling, PhD, Graham W

Similar presentations


Presentation on theme: "Lucy Wales, FRCS, MD, Martin Gosling, PhD, Graham W"— Presentation transcript:

1 The potassium channel opener levcromakalim causes expansive remodelling of experimental vein grafts 
Lucy Wales, FRCS, MD, Martin Gosling, PhD, Graham W. Taylor, PhD, Alun H. Davies, FRCS, MD, Janet T. Powell, MD, PhD  Journal of Vascular Surgery  Volume 44, Issue 1, Pages (July 2006) DOI: /j.jvs Copyright © 2006 The Society for Vascular Surgery Terms and Conditions

2 Fig 1 Schematic representation of anatomic landmarks and measurements made. Journal of Vascular Surgery  , DOI: ( /j.jvs ) Copyright © 2006 The Society for Vascular Surgery Terms and Conditions

3 Fig 2 Pharmokinetic studies of levcromakalim. A Hypotensive effect of levcromakalim in anesthetized normotensive rats. Blood pressure (mean ± SD) was transduced from an intra-aortic line, in 3 rats, in response to intravenous levcromakalim. B Rat plasma levcromakalim concentration following a single bolus of levcromakalim (100 μg/kg). The decay curve was identical in 2 rats, giving a half-life of 32.5 minutes. Journal of Vascular Surgery  , DOI: ( /j.jvs ) Copyright © 2006 The Society for Vascular Surgery Terms and Conditions

4 Fig 3 Rat thoracic vena cava. Elastic van Gieson staining shows the elastic laminae. The scale bar represents 50 μ. Journal of Vascular Surgery  , DOI: ( /j.jvs ) Copyright © 2006 The Society for Vascular Surgery Terms and Conditions

5 Fig 4 Vein grafts at 1 week. Examples from the placebo group are shown in A stained with hematoxylin and eosin (H&E) and in C stained with elastic van Gieson (EVG). Examples from the levcromakalim group are shown in B (H&E) and D (EVG). Note the periadventitial stripping (the result of processing for histology) in D. The scale bar represents 100 μ. Journal of Vascular Surgery  , DOI: ( /j.jvs ) Copyright © 2006 The Society for Vascular Surgery Terms and Conditions

6 Fig 5 Bromodeoxyuridine (BrdU) staining of vein grafts at 1 week. A, Control 0 staining. B, Example of levcromakalim treated group showing +1 medial staining for BrdU. C, Example from placebo group showing +3 medial staining for BrdU. The scale bar represents 100 μm. Journal of Vascular Surgery  , DOI: ( /j.jvs ) Copyright © 2006 The Society for Vascular Surgery Terms and Conditions

7 Fig 6 Vein grafts at 4 weeks. Examples from the placebo group are shown in A stained with hematoxylin and eosin (H&E) and in C stained with elastic van Gieson (EVG). Examples from the levcromakalim group are shown in B (H&E) and D (EVG). The scale bar represents 100 μm. Journal of Vascular Surgery  , DOI: ( /j.jvs ) Copyright © 2006 The Society for Vascular Surgery Terms and Conditions

8 Fig 7 Summary of the morphometric data at 4 weeks and characteristic cross-section of vein grafts from the levcromakalim and placebo groups. Example cross-sections of grafts are shown below the summary data with levcromakalim on the left and placebo on the right. Data are means ± SD. Journal of Vascular Surgery  , DOI: ( /j.jvs ) Copyright © 2006 The Society for Vascular Surgery Terms and Conditions


Download ppt "Lucy Wales, FRCS, MD, Martin Gosling, PhD, Graham W"

Similar presentations


Ads by Google